Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 88 citing articles:

Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Kristian B. Filion, Lisa M. Lix, Oriana HY Yu, et al.
BMJ (2020), pp. m3342-m3342
Open Access | Times Cited: 90
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
Sebastian Schneeweiß, Elisabetta Patorno
Endocrine Reviews (2021) Vol. 42, Iss. 5, pp. 658-690
Open Access | Times Cited: 86
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Björn Pasternak, Viktor Wintzell, Mads Melbye, et al.
BMJ (2020), pp. m1186-m1186
Open Access | Times Cited: 84
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S.P. Lam, Dae Jung Kim, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 606-615
Open Access | Times Cited: 78
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
Li Chunxing, Shuo Liang, Lingyan Gao, et al.
PLoS ONE (2021) Vol. 16, Iss. 2, pp. e0244689-e0244689
Open Access | Times Cited: 67
Sex-Based Differences in Heart Failure
Sadiya S. Khan, Lauren B. Beach, Clyde W. Yancy
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 15, pp. 1530-1541
Open Access | Times Cited: 43
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Yan Xie, Benjamin Bowe, Hong Xian, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 9, pp. 644-656
Closed Access | Times Cited: 40
Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation
Osung Kwon, Jun‐Pyo Myong, Yunhee Lee, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 14
Open Access | Times Cited: 30
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
Seung Jin Han, Kyoung Hwa Ha, Nami Lee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 682-691
Open Access | Times Cited: 68
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson, Neha J. Pagidipati, Vanita R. Aroda, et al.
Circulation (2021) Vol. 144, Iss. 1, pp. 74-84
Open Access | Times Cited: 55
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
Ann Wan-Chin Ling, Cze-Ci Chan, Shao‐Wei Chen, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 54
Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
Min Zhuo, Chelsea E. Hawley, Julie M. Paik, et al.
JAMA Network Open (2021) Vol. 4, Iss. 10, pp. e2130762-e2130762
Open Access | Times Cited: 52
SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
Min Zhuo, Julie M. Paik, Deborah J. Wexler, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 858-867.e1
Open Access | Times Cited: 51
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study
Oscar Hou In Chou, Vinod Kumar Chauhan, Cheuk To Chung, et al.
Gastric Cancer (2024)
Open Access | Times Cited: 6
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
David Thein, M. Christiansen, Ulrik M. Mogensen, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 40
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Elisabetta Patorno, Ajinkya Pawar, Deborah J. Wexler, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 442-454
Open Access | Times Cited: 40
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of …
Cardiology Discovery (2021) Vol. 1, Iss. 2, pp. 70-104
Open Access | Times Cited: 33
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 4, pp. 991-1028
Open Access | Times Cited: 32
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
Marta Baviera, Stefano Genovese, Vito Lepore, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 7, pp. 1484-1495
Closed Access | Times Cited: 27
Comparison of SGLT2 and DPP4 inhibitors on clinical outcomes in COPD patients with diabetes: A nationwide cohort study
Ting‐Chia Chang, Yingkuan Liang, Chih-Cheng Lai, et al.
Diabetes Research and Clinical Practice (2025), pp. 112122-112122
Closed Access
Page 1 - Next Page

Scroll to top